mantle cell lymphoma

MorphoSys has commenced patient dosing in a Phase II study of anti-CD19 antibody MOR208 for the treatment of non-Hodgkin’s lymphoma (NHL).

The open-label, multicentre trial will evaluate MOR208’s efficacy in patients with relapsed or refractory NHL.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

MorphoSys chief development officer Dr Arndt Schottelius said the MOR208 cancer programme has considerable potential.

"Evaluating MOR208 in NHL and B-ALL – building on the data we already have for CLL – should enable us to assess the therapeutic benefit and broader commercial potential of the molecule in haematological malignancies," Schottelius said.

"Broadening the drug’s development programme into additional indications is intended to maximise the value of this compound."

See Also:

Secondary outcome measures of the single-arm clinical trial include response duration, safety and pharmacokinetics of MOR208.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is scheduled to be conducted at sites across both Europe and the US, will enrol around120 patients in four separate sub-indications (FL, MCL, DLBCL and other forms of indolent NHL).

At present, the compound is also being evaluated in a Phase II trial in B-cell Acute Lymphoblastic Leukemia (B-ALL).

The company gained worldwide rights to the potent Fc-optimised anti-CD19 antibody through an exclusive license and collaboration agreement with Xencor in 2010.

Image: Intermediate magnification micrograph of mantle cell lymphoma of the terminal ileum. Endoscopic biopsy. H&E stain. Photo: Nephron.